Zacks Analyst Blog Highlights Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina

For immediate release

Chicago, IL – July 22, 2022 – announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Johnson & Johnson JNJ, Cigna Corp. CI, Vertex Pharmaceuticals Inc. VRTX, Xcel Energy Inc. XEL and Illumina, Inc. ILMN.

Here are highlights from Thursday’s analyst blog:

Key analyst reports for Johnson & Johnson, Cigna and Vertex

Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Cigna Corp. and Vertex Pharmaceuticals Inc. These research reports have been handpicked from the approximately 70 reports published by our team of analysts today.

You can see all research reports from today here >>>

Johnson & Johnson shares have gained +0.8% over the past year against the industry’s +20.3% gain Zacks Large Cap Pharmaceuticals. The company’s Covid vaccine effort has proven to be less than stellar, but the Zacks analyst believes JNJ’s diverse revenue base makes it relatively resilient amid macro turmoil.

Its pharmaceuticals unit is outperforming the market, supported by its flagship drugs, Darzalex and Stelara, and contributions from newer drugs, Erleada and Tremfya. Sales in the MedTech unit recovered in the first quarter and the company is focused on growing this business through new products.

However, consumer unit sales are suffering from external supply constraints. J&J is making rapid progress with its pipeline and line extensions. Several crucial data readings are expected in 2022. Headwinds like generic competition and pricing pressure persist. Although J&J has taken significant steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.

(You can read the full Johnson & Johnson research report here >>>)

Cigna shares have outperformed industry Zacks Insurance – Multi line over the past year (+17.0% vs -11.1%). The company’s revenues have grown steadily over the past few years, driven by acquisitions, superior operating performance and a high-quality product portfolio.

Streamlining the business through the divestiture of the group life and disability business will help it focus on key growth areas. An expected increase in the number of medical members thanks to a diversified product portfolio, an extensive agent network and superior service are major assets.

He resorted to cautious capital deployment moves. In June 2022, it signed a $3.5 billion accelerated share buyback agreement. However, high leverage can affect its financial flexibility. Rising operating costs could reduce its margins.

(You can read the full Cigna research report here >>>)

Summit shares have outperformed industry Zacks Medical – Biomedical and Genetics over the past year (+45.7% vs -36.7%). Sales of the company’s cystic franchise continue to grow thanks to its triple therapy, Trikafta/Kaftrio. New reimbursement agreements in non-US markets and brand expansion to younger age groups in the US are driving up Trikafta/Kaftrio sales.

Meanwhile, Vertex has an extensive non-CF clinical pipeline in six disease areas, which are rapidly advancing with impressive data presented recently from several programs, which have established proof of concept.

Vertex faces minimal competition in its core CF franchise. However, Vertex’s reliance solely on the CF franchise for commercial revenue is concerning. Vertex’s non-FC programs carry significant risks, which is concerning.

(You can read the full Vertex research report here >>>)

Other noteworthy reports we’re featuring today include Xcel Energy Inc. and Illumina, Inc.

Why haven’t you watched Zacks best action?

Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.

See Free Stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit for more information on the performance figures displayed in this press release.

Zacks names ‘only one best choice for doubling up’

From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.

It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could jump in at any moment.

This company could rival or surpass other recent Zacks stocks which are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one. year.

Free: See our best stock and our 4 finalists >>

Click to get this free report

Xcel Energy Inc. (XEL): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

Illumina, Inc. (ILMN): Free Stock Analysis Report

Cigna Corporation (CI): Free Stock Analysis Report

To read this article on, click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link